

From: [REDACTED]@sanofi.com>
Sent: 19 May 2020 22:24
To: GAUER Celine (SG-RECOVER)
Cc: [REDACTED] (SG-RECOVER); [REDACTED] (SG-RECOVER); [REDACTED] (SG-RECOVER)
Subject: RE: follow-up questionnaire
Attachments: questionnaire_Sanofi__19052020_FINAL.pdf
Categories: TO REGISTER

Dear Mrs Gauer,
Please find enclosed our Sanofi answer to the questionnaire on COVID-19 vaccines.
In line with our meeting discussion, the answers primarily focus on our most advanced vaccine in development: the [REDACTED] recombinant protein vaccine.
The second vaccine we have in development [REDACTED] in collaboration with [REDACTED] is mentioned only in selected questions.
We would be pleased to provide you any further explanation needed and follow-up our constructive discussion in the coming weeks.
Best regards

[REDACTED]
[REDACTED]
[REDACTED] Lyon
EU Transparency Register : 61291462/64-77



Please consider the environment before printing this email

De : [REDACTED]@ec.europa.eu [REDACTED]@ec.europa.eu>
Envoyé : mardi 12 mai 2020 18:00
À : [REDACTED]@sanofi.com>
Cc : [REDACTED]@sanofi.com>; Celine.Gauer@ec.europa.eu;
[REDACTED]@ec.europa.eu; [REDACTED]@ec.europa.eu
Objet : [EXTERNAL] follow-up questionnaire


EXTERNAL : Real sender is [REDACTED]@ec.europa.eu

Dear [REDACTED]

In follow-up to our call of yesterday, please find attached a letter by Céline Gauer, together with a questionnaire.

Kind regards



European Commission | Secretariat-General
BERL B-1049 Brussels/Belgium | Tel 

Disclaimer: This is an informal e-mail which should not be registered. The above text cannot be regarded as an official position of the European Commission; any views expressed are exclusively those of the author. It is intended solely for the person to whom it is addressed and may contain confidential information.